Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some cardiovascular risk-reduction and liver enzyme/jaundice safety information aligns with the provided label excerpts (1.1, 5.2), but multiple additional claims about mechanism, plaque prevention, alcohol-related liver pathology, severity framing (e.g., liver failure), and specific symptom manifestations are not supported by the supplied label sections. Several claims also rely on an external journal study, which is not present in the label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) reduces the risk of heart attacks and strokes.
Supported by 1.1 Prevention of Cardiovascular Disease (listed indications include reducing risk of myocardial infarction and stroke).
Lipitor can cause elevations in liver enzymes, which can indicate liver damage.
Supported by 5.2 Liver Dysfunction (statins associated with biochemical abnormalities of liver function/transaminase elevations).
Liver damage can manifest as jaundice (yellowing of the skin and eyes).
Supported by 5.2 Liver Dysfunction (one patient developed jaundice; LFT increases described).
Unsupported Statements
Lipitor belongs to the class of drugs called statins.
Not supported by the provided label excerpts in the dataset.
Statins work by inhibiting the production of cholesterol in the liver.
Mechanism statement not supported by the provided label excerpts.
Lipitor helps prevent the buildup of plaque in arteries.
Plaque-buildup prevention wording not supported by the provided label excerpts.
In rare cases, Lipitor-associated liver enzyme elevations can lead to more severe liver problems such as liver failure.
Label excerpt provided (5.2) does not support the specific framing of rare cases leading to liver failure.
Excessive alcohol consumption can cause inflammation and scarring in the liver.
Provided 5.2 excerpt supports caution with substantial alcohol and history of liver disease, but does not support the specific inflammation/scarring claim.
Excess alcohol consumption can lead to fatty liver disease and cirrhosis.
Not supported by the provided 5.2 excerpt.
Even moderate drinking can increase the risk of liver damage, particularly when combined with other risk factors.
Specific claim about 'moderate' drinking and combination risk is not supported by the provided 5.2 excerpt.
Combining Lipitor and alcohol increases the risk of liver damage.
Partially supported at most by the caution language, but the dataset flags this as only partially supported; no full label support for the specific risk-increase framing as stated.
A study in the Journal of Clinical Gastroenterology found that individuals taking statins like Lipitor were more likely to experience liver damage when consuming excessive amounts of alcohol.
No such external study information is present in the provided label excerpts.
Liver damage can manifest as fatigue.
Not supported by the provided label excerpts.
Liver damage can manifest as nausea and vomiting.
Not supported by the provided label excerpts.
Liver damage can manifest as abdominal pain in the upper right quadrant.
Not supported by the provided label excerpts.
Liver damage can manifest as dark urine.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
No mention of label-recommended monitoring for liver function tests (prior to therapy, at 12 weeks after initiation and dose increase, and periodically) and management guidance (monitor until resolved; consider dose reduction/withdrawal if ALT/AST persist >3×ULN).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
While core safety concepts supported by 5.2 are included (transaminase elevations and jaundice), multiple additional alcohol-related liver pathology and symptom-manifestation claims are not supported by the provided label excerpts. This may mislead users about expected symptoms and the nature/extent of alcohol-related risk beyond what the supplied label text establishes.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several mechanism, alcohol-liver pathology, and specific symptom claims are not supported by the provided label excerpts (notably the 5.2 Liver Dysfunction section) and one claim cites an external journal study not present in the label.
Suggested Improvement
Restrict statements to what the provided label excerpts support: cardiovascular risk reduction (1.1), liver enzyme abnormalities and jaundice (5.2), label caution regarding substantial alcohol/history of liver disease (5.2), and include the label’s liver-function monitoring and management recommendations.